PUBLIC COMPANY
saveEnveda Biosciences Inc
updated 2mo ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- phase2A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- phase2ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
- phase1Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis
🐶 Hiring Signal
Where Enveda Biosciences Inc is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaImmunology & Inflammation 1
News
- Enveda, an AI drugmaker, banks $311M in venture fundingEnveda, which is using AI tools to mine plants and microbes for drug prospects, has three candidates in human testing for immune diseases and obesity.biopharma_dive · 10d ago
- AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease pushTech darling Enveda has raised a total of $845 million in the past six years. The latest funding round is intended to pave the way for an IPO someday.biospace · 10d ago
- Enveda reaps $311M series E to feed ambition to become a ‘household name’Enveda has raised a $311 million series E round, positioning the nature-derived drug discovery company to pursue its goal of becoming a household name over the next decade.fiercebiotech · 10d ago
- Chutes & Ladders—Vivace revs up C-suite ahead of pivotal pushVivace Therapeutics has named Craig Gibbs, Ph.D., as its new president and CEO.fiercebiotech · 1mo ago
comments(0)
5-min edit window · permanent after that